bruker - BRKR

BRKR

Close Chg Chg %
55.29 1.71 3.09%

Closed Market

57.00

+1.71 (3.09%)

Volume: 3.34M

Last Updated:

Dec 20, 2024, 4:00 PM EDT

Company Overview: bruker - BRKR

BRKR Key Data

Open

$55.33

Day Range

55.27 - 58.08

52 Week Range

48.07 - 94.86

Market Cap

$8.38B

Shares Outstanding

151.60M

Public Float

102.99M

Beta

1.18

Rev. Per Employee

N/A

P/E Ratio

26.62

EPS

$2.08

Yield

36.17%

Dividend

$0.05

EX-DIVIDEND DATE

Dec 2, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.56M

 

BRKR Performance

1 Week
 
-1.26%
 
1 Month
 
-0.12%
 
3 Months
 
-15.61%
 
1 Year
 
-22.68%
 
5 Years
 
10.44%
 

BRKR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About bruker - BRKR

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

BRKR At a Glance

Bruker Corp.
40 Manning Road
Billerica, Massachusetts 01821
Phone 1-978-663-3660 Revenue 2.96B
Industry Medical Specialties Net Income 427.20M
Sector Health Technology 2023 Sales Growth 17.142%
Fiscal Year-end 12 / 2024 Employees 9,707
View SEC Filings

BRKR Valuation

P/E Current 26.623
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.319
Price to Sales Ratio 3.649
Price to Book Ratio 7.745
Price to Cash Flow Ratio 30.895
Enterprise Value to EBITDA 19.665
Enterprise Value to Sales 3.961
Total Debt to Enterprise Value 0.117

BRKR Efficiency

Revenue/Employee 305,398.166
Income Per Employee 44,009.478
Receivables Turnover 4.768
Total Asset Turnover 0.754

BRKR Liquidity

Current Ratio 1.80
Quick Ratio 0.995
Cash Ratio 0.406

BRKR Profitability

Gross Margin 51.165
Operating Margin 16.269
Pretax Margin 18.357
Net Margin 14.411
Return on Assets 10.868
Return on Equity 34.299
Return on Total Capital 15.496
Return on Invested Capital 17.221

BRKR Capital Structure

Total Debt to Total Equity 100.174
Total Debt to Total Capital 50.044
Total Debt to Total Assets 32.462
Long-Term Debt to Equity 89.682
Long-Term Debt to Total Capital 44.802
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bruker - BRKR

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
1.99B 2.42B 2.53B 2.96B
Sales Growth
-4.11% +21.66% +4.67% +17.14%
Cost of Goods Sold (COGS) incl D&A
1.04B 1.20B 1.22B 1.45B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
80.50M 89.20M 88.80M 114.90M
Depreciation
44.70M 51.80M 51.70M 67.80M
Amortization of Intangibles
35.80M 37.40M 37.10M 47.10M
COGS Growth
-2.51% +15.42% +1.59% +18.27%
Gross Income
943.60M 1.21B 1.31B 1.52B
Gross Income Growth
-5.81% +28.55% +7.72% +16.09%
Gross Profit Margin
+47.48% +50.17% +51.63% +51.17%
2020 2021 2022 2023 5-year trend
SG&A Expense
666.60M 782.00M 843.30M 1.02B
Research & Development
198.00M 220.80M 235.90M 294.80M
Other SG&A
468.60M 561.20M 607.40M 729.40M
SGA Growth
-3.10% +17.31% +7.84% +21.45%
Other Operating Expense
2.50M 2.80M 3.80M 10.30M
Unusual Expense
16.50M 14.80M 21.50M 31.80M
EBIT after Unusual Expense
258.00M 413.40M 438.00M 450.50M
Non Operating Income/Expense
(17.80M) (5.50M) (8.00M) 110.10M
Non-Operating Interest Income
3.20M 900.00K 4.10M 7.50M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
14.40M 14.30M 16.10M 16.40M
Interest Expense Growth
-10.00% -0.69% +12.59% +1.86%
Gross Interest Expense
14.40M 14.30M 16.10M 16.40M
Interest Capitalized
- - - -
-
Pretax Income
225.80M 393.60M 413.90M 544.20M
Pretax Income Growth
-19.47% +74.31% +5.16% +31.48%
Pretax Margin
+11.36% +16.28% +16.36% +18.36%
Income Tax
64.40M 113.00M 116.40M 117.70M
Income Tax - Current - Domestic
(1.00M) 2.20M (7.90M) 4.70M
Income Tax - Current - Foreign
85.40M 118.00M 135.30M 138.70M
Income Tax - Deferred - Domestic
(5.90M) (10.30M) (4.80M) (22.90M)
Income Tax - Deferred - Foreign
(14.10M) 3.10M (6.20M) (2.80M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
161.40M 280.60M 298.50M 428.50M
Minority Interest Expense
3.60M 3.50M 1.90M 1.30M
Net Income
157.80M 277.10M 296.60M 427.20M
Net Income Growth
-19.98% +75.60% +7.04% +44.03%
Net Margin Growth
+7.94% +11.46% +11.72% +14.41%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
157.80M 277.10M 296.60M 427.20M
Preferred Dividends
- - - -
-
Net Income Available to Common
157.80M 277.10M 296.60M 427.20M
EPS (Basic)
1.0287 1.8302 1.996 2.918
EPS (Basic) Growth
-19.04% +77.91% +9.06% +46.19%
Basic Shares Outstanding
153.40M 151.40M 148.60M 146.40M
EPS (Diluted)
1.0207 1.8123 1.9853 2.9022
EPS (Diluted) Growth
-18.95% +77.55% +9.55% +46.18%
Diluted Shares Outstanding
154.60M 152.90M 149.40M 147.20M
EBITDA
355.00M 517.40M 548.30M 597.20M
EBITDA Growth
-8.86% +45.75% +5.97% +8.92%
EBITDA Margin
+17.86% +21.40% +21.67% +20.15%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 72.417
Number of Ratings 15 Current Quarters Estimate 0.737
FY Report Date 12 / 2024 Current Year's Estimate 2.387
Last Quarter’s Earnings 0.60 Median PE on CY Estimate N/A
Year Ago Earnings 2.58 Next Fiscal Year Estimate 2.735
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 13 15 15
Mean Estimate 0.74 0.53 2.39 2.74
High Estimates 0.80 0.58 2.44 3.04
Low Estimate 0.71 0.41 2.36 2.50
Coefficient of Variance 3.10 7.99 0.85 4.13

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 6 6
OVERWEIGHT 2 2 0
HOLD 5 3 3
UNDERWEIGHT 0 0 0
SELL 1 2 2
MEAN Overweight Overweight Overweight

Insider Actions for Bruker - BRKR

Date Name Shares Transaction Value
Nov 26, 2024 William Alderman Linton Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 William Alderman Linton Director 45,425 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $19.12 per share 868,526.00
Aug 8, 2024 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 70,382 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $63.54 per share 4,472,072.28
Aug 8, 2024 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 69,394 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $62.16 per share 4,313,531.04
Mar 13, 2024 Frank H. Laukien PRESIDENT & CEO; Director 38,326,507 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $73.36 per share 2,811,632,553.52
Mar 7, 2024 Hermann Fritz Requardt Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2024 Hermann Fritz Requardt Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2024 Hermann Fritz Requardt Director 23,147 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $89.61 per share 2,074,202.67
Mar 7, 2024 Hermann Fritz Requardt Director 24,375 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $90.1 per share 2,196,187.50
Mar 7, 2024 Hermann Fritz Requardt Director 38,147 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24 per share 915,528.00
Mar 7, 2024 Hermann Fritz Requardt Director 28,147 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.15 per share 510,868.05
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 28,780 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.5 per share 1,251,930.00
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 29,863 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $34.02 per share 1,015,939.26
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 31,766 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $41.95 per share 1,332,583.70
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 32,384 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62 per share 2,007,808.00
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 17,065 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.3 per share 1,421,514.50
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 923 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2024 Burkhard Prause PRES. & CEO, BRUKER BEST 1,854 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Bruker in the News